Pre-Clinical Trial to Evaluate the Efficacy of Delayed Administration of Ixazomib in the Prophylaxis of Chronic Graft-Versus-Host Disease

Conclusion: In vitro studies show that ixazomib induces apoptosis on activated T lymphocytes and decreases the expression of activation markers. Our in vivo model indicates that the combination of CyA and ixazomib for the prevention of pcGvHD and cGVHD after allogeneic HSCT is promising and merits further investigation in clinical trials.Figure 1. Survival of pcGvHD.Figure 2. Score graphic of scleroderma cGvHD. BM - Bone marrow, mice that were transplanted with BM from BALBc mice (Syngeneic).DisclosuresRamos: Takeda Oncology: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Ramos, T., Rodriguez-Gil, A., Nufer, M., Barbado, M. V., Guerrero, E. G., Caracuel-Garcia, R., Caballero-Velazquez, T., Perez-Simon, J. A. Tags: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster III Source Type: research